Drug · DIN 02523930
OZEMPIC
DISPENSES 2 MG DOSES. MULTIDOSE PREFILLED PEN
Authorized, not yet reported as sold
Authorized for sale in Canada; the company has not yet told Health Canada that it is on the market.
Status Approved since January 4, 2022.
- Drug Identification Number (DIN)
- 02523930
- Company (DIN owner)
- Novo Nordisk Canada IncMississauga, Ontario, Canada
- Schedule
- Prescription; Schedule D
- Dosage form
- Solution
- Route
- Subcutaneous
- Therapeutic class (ATC)
- Semaglutide A10BJ06
- Class
- Human
- Record last updated
- August 13, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| SEMAGLUTIDE | 2.68 MG | ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- January 4, 2022: NOC 27330Supplement to a New Drug Submission (SNDS) · New presentation
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “ozempic”. A notice may cover another product or only some lots: read it to see what it covers.
- Ozempic Solution: Cracked glass cartridgesOctober 31, 2025 · Biologic or vaccine · Product quality · Type II
Other DINs named OZEMPIC
- DIN 02471469 · Marketed
- DIN 02540258 · Marketed
- DIN 02471477 · Dormant
- DIN 02562618 · Approved
- DIN 02562626 · Approved